Continental Advisors LLC decreased its position in Myriad Genetics, Inc. (NASDAQ:MYGN) by 41.4% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 35,200 shares of the company’s stock after selling 24,900 shares during the period. Continental Advisors LLC owned 0.05% of Myriad Genetics worth $1,274,000 at the end of the most recent quarter.
A number of other institutional investors have also recently bought and sold shares of the stock. Vanguard Group Inc. boosted its holdings in Myriad Genetics by 0.9% in the second quarter. Vanguard Group Inc. now owns 6,307,738 shares of the company’s stock valued at $162,992,000 after acquiring an additional 56,708 shares during the last quarter. Dimensional Fund Advisors LP boosted its holdings in Myriad Genetics by 4.4% in the third quarter. Dimensional Fund Advisors LP now owns 3,580,081 shares of the company’s stock valued at $129,527,000 after acquiring an additional 149,865 shares during the last quarter. Thrivent Financial For Lutherans boosted its holdings in Myriad Genetics by 7,026.7% in the second quarter. Thrivent Financial For Lutherans now owns 2,742,340 shares of the company’s stock valued at $70,862,000 after acquiring an additional 2,703,860 shares during the last quarter. Northern Trust Corp lifted its stake in Myriad Genetics by 31.1% in the second quarter. Northern Trust Corp now owns 1,292,588 shares of the company’s stock valued at $33,400,000 after buying an additional 306,276 shares during the period. Finally, Russell Investments Group Ltd. lifted its stake in Myriad Genetics by 7.3% in the third quarter. Russell Investments Group Ltd. now owns 1,151,915 shares of the company’s stock valued at $41,676,000 after buying an additional 78,798 shares during the period.
Several equities analysts have weighed in on the company. Zacks Investment Research raised Myriad Genetics from a “hold” rating to a “strong-buy” rating and set a $42.00 target price on the stock in a research note on Tuesday, October 17th. Cowen reissued a “hold” rating and issued a $25.00 target price on shares of Myriad Genetics in a research note on Sunday, September 17th. Deutsche Bank raised Myriad Genetics from a “sell” rating to a “hold” rating and cut their target price for the company from $27.86 to $15.00 in a research note on Friday, August 18th. Morgan Stanley reissued an “underweight” rating and issued a $24.00 target price (up previously from $17.00) on shares of Myriad Genetics in a research note on Friday, October 6th. Finally, Stephens reissued an “overweight” rating and issued a $40.00 target price (up previously from $36.00) on shares of Myriad Genetics in a research note on Friday, September 22nd. Two investment analysts have rated the stock with a sell rating, eight have given a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company’s stock. Myriad Genetics currently has an average rating of “Hold” and a consensus target price of $28.10.
Myriad Genetics (NASDAQ:MYGN) last released its quarterly earnings results on Tuesday, November 7th. The company reported $0.26 EPS for the quarter, topping the Zacks’ consensus estimate of $0.21 by $0.05. The company had revenue of $190.20 million for the quarter, compared to analyst estimates of $183.52 million. Myriad Genetics had a return on equity of 9.54% and a net margin of 13.28%. Myriad Genetics’s revenue was up 7.2% compared to the same quarter last year. During the same quarter last year, the firm posted $0.23 earnings per share. research analysts forecast that Myriad Genetics, Inc. will post 1.05 EPS for the current year.
In other news, insider Alexander Ford sold 3,031 shares of the firm’s stock in a transaction dated Monday, November 13th. The stock was sold at an average price of $31.64, for a total transaction of $95,900.84. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Company insiders own 6.70% of the company’s stock.
Myriad Genetics Company Profile
Myriad Genetics, Inc is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual’s risk for developing disease later in life, identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to enable optimal treatment, or assess a patient’s risk of disease progression and disease recurrence.
Want to see what other hedge funds are holding MYGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Myriad Genetics, Inc. (NASDAQ:MYGN).
Receive News & Ratings for Myriad Genetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.